What is the appropriate heparin dosing for treating venous thromboembolism?

Heparin Dosing for VTE Treatment

For treating venous thromboembolism with unfractionated heparin, use weight-based intravenous dosing: 80 units/kg bolus followed by 18 units/kg/hour continuous infusion, with dose adjustments targeting an aPTT of 1.5-2.5 times control (corresponding to anti-Factor Xa levels of 0.3-0.7 IU/mL). 1, 2

Preferred Anticoagulation Strategy

Low-molecular-weight heparin (LMWH) or fondaparinux is preferred over unfractionated heparin for initial VTE treatment 1. However, when unfractionated heparin is selected (such as in severe renal failure, high bleeding risk requiring reversibility, or when thrombolysis may be needed), proper dosing is critical.

Unfractionated Heparin Dosing Regimens

Intravenous Administration (Preferred Route)

• Initial bolus: 80 units/kg IV
• Continuous infusion: 18 units/kg/hour
• Monitoring: Check aPTT approximately every 4 hours initially, then at appropriate intervals
• Target aPTT: 1.5-2.5 times control (equivalent to anti-Factor Xa 0.3-0.7 IU/mL) 1, 3, 4, 2

The weight-based approach is superior to fixed dosing. Studies demonstrate that patients achieving therapeutic aPTT within 24 hours have significantly lower recurrence rates and mortality compared to those with delayed therapeutic anticoagulation 4.

Subcutaneous Administration (Alternative)

If IV access is problematic:

• Initial dose: 333 units/kg subcutaneous, followed by
• Maintenance: 250 units/kg subcutaneous every 12 hours 1

This subcutaneous regimen was shown equally safe and effective as IV heparin in the FIDO trial 1.

Dose Adjustment Protocol

Use an aPTT-based nomogram validated at your institution 3:

• aPTT <1.2× control (<35s): 80 units/kg bolus; increase infusion by 4 units/kg/hour
• aPTT 1.2-1.5× control (35-45s): 40 units/kg bolus; increase infusion by 2 units/kg/hour
• aPTT 1.5-2.3× control (46-70s): No change
• aPTT 2.3-3.0× control (71-90s): Reduce infusion by 2 units/kg/hour
• aPTT >3.0× control (>90s): Stop infusion for 1 hour, then reduce by 3 units/kg/hour 3

Critical Monitoring Requirements

• Baseline labs: CBC, aPTT, PT/INR, renal and hepatic function 5
• Platelet monitoring: Every 2-3 days from day 4 to day 14 to screen for heparin-induced thrombocytopenia (HIT), which occurs in up to 5% of patients on UFH 1
• Hemoglobin/hematocrit: Monitor for bleeding 2

Alternative LMWH Dosing (Preferred Agents)

When LMWH is chosen instead:

Enoxaparin:

• 1 mg/kg subcutaneous every 12 hours, OR
• 1.5 mg/kg subcutaneous once daily (widely used for outpatient DVT/small PE) 1

Dalteparin:

• 200 units/kg subcutaneous once daily (FDA-approved for cancer patients) 1, 5

Fondaparinux (weight-based):

• <50 kg: 5 mg daily
• 50-100 kg: 7.5 mg daily

• 100 kg: 10 mg daily 1

Special Populations

Obesity: Standard weight-based protocols with maximum dose caps can cause significant delays in achieving therapeutic anticoagulation. Consider using adjusted body weight: IBW + 0.3(ABW - IBW) or IBW + 0.4(ABW - IBW) 6.

Renal failure (CrCl <30 mL/min):

• Avoid LMWH and fondaparinux
• Use unfractionated heparin with standard weight-based dosing 1

Cancer patients: LMWH preferred over UFH for the first 6 months; dalteparin has the strongest evidence in this population 7, 5.

Common Pitfalls to Avoid

1. Fixed dosing instead of weight-based: Results in 3-fold higher recurrence rates 4
2. Delaying therapeutic anticoagulation: Failure to achieve therapeutic aPTT within 24 hours significantly increases recurrence risk and mortality 4
3. Inadequate platelet monitoring: Missing HIT can lead to catastrophic thrombosis 1
4. Using maximum dose caps in obese patients: Can delay therapeutic anticoagulation by >50 hours 6
5. Confusing heparin vials with catheter lock flush vials: Fatal medication errors have occurred 2

Duration and Transition

• Overlap heparin with warfarin for minimum 5 days AND until INR ≥2.0 for at least 24 hours 1
• For direct oral anticoagulants, follow specific transition protocols per drug labeling 2